Literature DB >> 2581140

Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein.

J R Feramisco, R Clark, G Wong, N Arnheim, R Milley, F McCormick.   

Abstract

The proteins encoded by the ras oncogene are thought to trigger expression of the transformed phenotype in some types of cancer cells. In human cells, the ras protein family consists of several members including normal (proto-oncogene) and mutant (oncogene) forms. In general, the proto-oncogene forms are thought to be involved in the normal growth control of cells, while the mutant forms (which apparently result from somatic mutation of the normal ras genes) appear to be responsible, in part, for the loss of normal growth control. On microinjection into living normal cells, the purified ras oncogene protein (p21) induces a characteristic loss of growth control in cells within several hours. The mutant forms of the different ras proteins typically contain a single amino-acid change, usually at position 12 or less frequently at position 61. Here we report that microinjection of antibodies specific for amino acid 12 of the oncogenic v-Ki-ras protein into cells transformed by this protein causes a transient reversion of the cells to a normal phenotype. The fact that this antibody inhibits binding of GTP to the v-Ki-ras protein supports the notion that GTP binding is essential to the transforming function of this oncogene product.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581140     DOI: 10.1038/314639a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  35 in total

Review 1.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

Review 2.  The biochemistry of ras p21.

Authors:  R J Grand; D Owen
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

3.  Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells.

Authors:  R Plattner; M J Anderson; K Y Sato; C L Fasching; C J Der; E J Stanbridge
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Expression of H-ras correlates with metastatic potential: evidence for direct regulation of the metastatic phenotype in 10T1/2 and NIH 3T3 cells.

Authors:  S E Egan; G A McClarty; L Jarolim; J A Wright; I Spiro; G Hager; A H Greenberg
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

5.  Monoclonal antibody specific for an activated RAS protein.

Authors:  W P Carney; D Petit; P Hamer; C J Der; T Finkel; G M Cooper; M Lefebvre; H Mobtaker; R Delellis; A S Tischler
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 6.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 7.  Targeting Ras with Macromolecules.

Authors:  Dehua Pei; Kuangyu Chen; Hui Liao
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

8.  Chimeric proteins define variable and essential regions of Ha-ras-encoded protein.

Authors:  D G Lowe; M Ricketts; A D Levinson; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Oncogene amplification during tumorigenesis of established rat fibroblasts reversibly transformed by activated human ras oncogenes.

Authors:  E Winter; M Perucho
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

10.  Inhibition of RAS function through targeting an allosteric regulatory site.

Authors:  Russell Spencer-Smith; Akiko Koide; Yong Zhou; Raphael R Eguchi; Fern Sha; Priyanka Gajwani; Dianicha Santana; Ankit Gupta; Miranda Jacobs; Erika Herrero-Garcia; Jacqueline Cobbert; Hugo Lavoie; Matthew Smith; Thanashan Rajakulendran; Evan Dowdell; Mustafa Nazir Okur; Irina Dementieva; Frank Sicheri; Marc Therrien; John F Hancock; Mitsuhiko Ikura; Shohei Koide; John P O'Bryan
Journal:  Nat Chem Biol       Date:  2016-11-07       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.